SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CYPB - Cypress BioScience
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: growthvalue who wrote (393)9/16/1998 12:46:00 PM
From: brent gephart  Read Replies (2) of 586
 
Yes. From Cypresses Annual report they say that "over 10% of RA sufferers are expected to fail conventional therapies." With over 200,000 new patients being diagnosed each year.

So that means at least 20,000 patients could be a patient for the RA column each year. With 12 treatments at $1,000 ( not sure of price, company said they were going to change price, didn't they?) each. That equals 240,000 treatments at a collective cost of $240,000,000. Of course I believe these numbers are for the world. But that does not take into account the 7 million people with RA of which 700,000 of them do not respond to conventional RA therapies.

Brent
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News